AU2020292256B2 - Adeno-associated virus compositions for ARSA gene transfer and methods of use thereof - Google Patents

Adeno-associated virus compositions for ARSA gene transfer and methods of use thereof Download PDF

Info

Publication number
AU2020292256B2
AU2020292256B2 AU2020292256A AU2020292256A AU2020292256B2 AU 2020292256 B2 AU2020292256 B2 AU 2020292256B2 AU 2020292256 A AU2020292256 A AU 2020292256A AU 2020292256 A AU2020292256 A AU 2020292256A AU 2020292256 B2 AU2020292256 B2 AU 2020292256B2
Authority
AU
Australia
Prior art keywords
amino acid
seq
gly
capsid protein
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2020292256A
Other languages
English (en)
Other versions
AU2020292256A1 (en
Inventor
Hillard RUBIN
Albert Barnes Seymour
Thia Baboval ST. MARTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Homology Medicines Inc
Original Assignee
Homology Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Homology Medicines Inc filed Critical Homology Medicines Inc
Publication of AU2020292256A1 publication Critical patent/AU2020292256A1/en
Application granted granted Critical
Publication of AU2020292256B2 publication Critical patent/AU2020292256B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020292256A 2019-06-10 2020-06-09 Adeno-associated virus compositions for ARSA gene transfer and methods of use thereof Ceased AU2020292256B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962859539P 2019-06-10 2019-06-10
US62/859,539 2019-06-10
US201962866374P 2019-06-25 2019-06-25
US62/866,374 2019-06-25
US201962915523P 2019-10-15 2019-10-15
US62/915,523 2019-10-15
US202062960487P 2020-01-13 2020-01-13
US62/960,487 2020-01-13
US202062987858P 2020-03-10 2020-03-10
US62/987,858 2020-03-10
US202063010970P 2020-04-16 2020-04-16
US63/010,970 2020-04-16
PCT/US2020/036846 WO2020251954A1 (en) 2019-06-10 2020-06-09 Adeno-associated virus compositions for arsa gene transfer and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2020292256A1 AU2020292256A1 (en) 2022-01-06
AU2020292256B2 true AU2020292256B2 (en) 2023-01-19

Family

ID=73782242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020292256A Ceased AU2020292256B2 (en) 2019-06-10 2020-06-09 Adeno-associated virus compositions for ARSA gene transfer and methods of use thereof

Country Status (15)

Country Link
US (1) US20220204991A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980447A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022536338A (cg-RX-API-DMAC7.html)
KR (1) KR20220035107A (cg-RX-API-DMAC7.html)
CN (1) CN114502575A (cg-RX-API-DMAC7.html)
AU (1) AU2020292256B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024855A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142932A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003295A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016797A2 (cg-RX-API-DMAC7.html)
IL (1) IL288863A (cg-RX-API-DMAC7.html)
MX (1) MX2021015076A (cg-RX-API-DMAC7.html)
PE (1) PE20220233A1 (cg-RX-API-DMAC7.html)
TW (1) TW202112807A (cg-RX-API-DMAC7.html)
WO (1) WO2020251954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769577C1 (ru) * 2021-06-01 2022-04-04 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Препарат для лечения метахроматической лейкодистрофии и способ ее лечения
CN119213120A (zh) * 2022-05-16 2024-12-27 建新公司 治疗异染性脑白质营养不良的方法
MA71631A (fr) 2022-07-29 2025-05-30 Regeneron Pharmaceuticals, Inc. Particules virales reciblées vers le récepteur 1 de transferrine
WO2024036250A2 (en) * 2022-08-10 2024-02-15 Homology Medicines, Inc. Adeno-associated virus compositions for arsa gene transfer and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152841A1 (en) * 2018-02-01 2019-08-08 Homology Medicines, Inc. Adeno-associated virus compositions for pah gene transfer and methods of use thereof
WO2020168222A1 (en) * 2019-02-15 2020-08-20 Generation Bio Co. Modulation of rep protein activity in closed-ended dna (cedna) production
WO2020227166A1 (en) * 2019-05-03 2020-11-12 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of metachromatic leukodystrophy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839696B2 (en) * 2010-04-30 2017-12-12 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US10738326B2 (en) * 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
EP3632923A1 (en) * 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
JP6836999B2 (ja) * 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
KR20220082100A (ko) * 2015-05-15 2022-06-16 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 치료적 전달
EP3929287A3 (en) * 2015-06-18 2022-04-13 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152841A1 (en) * 2018-02-01 2019-08-08 Homology Medicines, Inc. Adeno-associated virus compositions for pah gene transfer and methods of use thereof
WO2020168222A1 (en) * 2019-02-15 2020-08-20 Generation Bio Co. Modulation of rep protein activity in closed-ended dna (cedna) production
WO2020227166A1 (en) * 2019-05-03 2020-11-12 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of metachromatic leukodystrophy

Also Published As

Publication number Publication date
AU2020292256A1 (en) 2022-01-06
IL288863A (en) 2022-02-01
US20220204991A1 (en) 2022-06-30
BR112021024855A2 (pt) 2022-05-03
TW202112807A (zh) 2021-04-01
EP3980447A1 (en) 2022-04-13
KR20220035107A (ko) 2022-03-21
CN114502575A (zh) 2022-05-13
PE20220233A1 (es) 2022-02-07
CA3142932A1 (en) 2020-12-17
JP2022536338A (ja) 2022-08-15
MX2021015076A (es) 2022-06-02
CO2021016797A2 (es) 2022-01-17
WO2020251954A1 (en) 2020-12-17
EP3980447A4 (en) 2023-07-26
CL2021003295A1 (es) 2022-09-23

Similar Documents

Publication Publication Date Title
AU2020205228B2 (en) Gene therapies for lysosomal disorders
AU2020260491B2 (en) Gene therapies for lysosomal disorders
AU2023214366B2 (en) Gene therapies for lysosomal disorders
KR20220006527A (ko) 리소좀 장애에 대한 유전자 요법
KR20230066360A (ko) 신경퇴행성 장애를 위한 유전자 요법
KR20220035107A (ko) Arsa 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
KR20210150486A (ko) 리소좀 장애에 대한 유전자 요법
KR20230051529A (ko) 리소좀 장애에 대한 유전자 요법
KR102545070B1 (ko) 안구 장애에 대한 유전자 치료
HK40048832A (en) Gene therapies for lysosomal disorders
HK40046514A (en) Gene therapies for lysosomal disorders
HK40048832B (en) Gene therapies for lysosomal disorders
HK40047428A (en) Gene therapies for lysosomal disorders
HK40067825A (zh) 用於溶酶体障碍的基因疗法
CN114025806A (zh) 用于溶酶体障碍的基因疗法
HK40109651A (en) Recombinant tert-encoding viral genomes and vectors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired